We are committed to developing drugs that take a unique approach to precision oncology by focusing on broad mechanisms that have multiple links to oncogenic driver pathways in select patients.
We have developed a diverse pipeline consisting of six distinct programs spanning methyltransferases, kinases, protein-protein interactions, and targeted protein degraders. Our pipeline is geared towards serving patients with high unmet medical need where there are limited or no treatment options.
